Patino Willmar, Thomas Amanda, Jain Sanjana, Del Rosso James Q, Issa Naiem T
Dr. Patino is with Forefront Dermatology in Manitowoc, Wisconsin.
Ms. Thomas is with the Creighton University School of Medicine in Phoenix, Arizona.
J Clin Aesthet Dermatol. 2025 Mar;18(3):42-50.
Glucagon-like peptide-1 (GLP-1) is a hormone produced in response to meal intake by endocrine intestinal cells. GLP-1 binds to its receptors which are expressed on various cells throughout the body. GLP-1 receptors (GLP-1R) have become a target for the treatment of diabetes mellitus and weight loss, and GLP-1 receptor agonist (GLP-1RA) use has become more common among patients. In addition to the anti-hyperglycemic effects, recent studies have exhibited anti-inflammatory effects of GLP-1RAs. Current research surrounding GLP-1Rs and GLP-1R agonism in dermatology is limited. This review aims to describe the current knowledge of GLP-1Rs and GLP-1RA use in dermatology and suggest future directions.
A literature search focused on GLP-1RAs and their effect on cutaneous disease processes was performed across various databases. The databases were searched through May 2024.
The use of GLP-1RAs have shown promising anti-inflammatory effects and improvement in wound healing, psoriasis, and hidradenitis suppurativa. Several cutaneous adverse reactions to GLP-1RAs were also identified with injection site pruritus, erythema, and rash being the most commonly reported.
Current literature is limited to case reports and small-scale studies.
The literature suggests anti-inflammatory effects of GLP-1RAs may provide direct benefit in the treatment of dermatologic conditions independent of glucose control in addition to indirect improvement via modulation of blood glucose and weight loss. Further studies investigating the implications of GLP-1RA use and the possible therapeutic potential of GLP-1RAs in inflammatory skin conditions are warranted.
胰高血糖素样肽-1（GLP-1）是一种由肠道内分泌细胞在进食后产生的激素。GLP-1与其在全身各种细胞上表达的受体结合。GLP-1受体（GLP-1R）已成为治疗糖尿病和减肥的靶点，GLP-1受体激动剂（GLP-1RA）在患者中的使用越来越普遍。除了降血糖作用外，最近的研究还显示了GLP-1RA的抗炎作用。目前关于皮肤科中GLP-1R和GLP-1R激动作用的研究有限。本综述旨在描述目前关于GLP-1R和GLP-1RA在皮肤科应用的知识，并提出未来的研究方向。
对多个数据库进行文献检索，重点关注GLP-1RA及其对皮肤疾病过程的影响。检索截至2024年5月。
GLP-1RA的使用已显示出有前景的抗炎作用，并改善了伤口愈合、银屑病和化脓性汗腺炎。还发现了几种与GLP-1RA相关的皮肤不良反应，其中注射部位瘙痒、红斑和皮疹是最常报告的。
目前的文献仅限于病例报告和小规模研究。
文献表明，GLP-1RA的抗炎作用可能在治疗皮肤病方面提供直接益处，这独立于血糖控制，此外还可通过调节血糖和减轻体重间接改善病情。有必要进一步研究GLP-1RA使用的影响以及GLP-1RA在炎症性皮肤病中的潜在治疗潜力。
